Adamis Pharmaceuticals Corp (NASDAQ:ADMP)’s stock price was up 6% during mid-day trading on Tuesday . The company traded as high as $0.80 and last traded at $0.78, approximately 881,065 shares traded hands during trading. An increase of 95% from the average daily volume of 452,071 shares. The stock had previously closed at $0.74.

A number of brokerages recently issued reports on ADMP. Maxim Group set a $6.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 9th. Dawson James initiated coverage on shares of Adamis Pharmaceuticals in a research note on Tuesday, July 2nd. They set a “buy” rating for the company. ValuEngine cut shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Zacks Investment Research downgraded shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. Finally, B. Riley raised shares of Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a research report on Tuesday, July 23rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $3.87.

The stock’s 50 day moving average price is $1.00 and its 200 day moving average price is $1.66. The company has a current ratio of 1.04, a quick ratio of 0.79 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $45.50 million, a price-to-earnings ratio of -0.78 and a beta of 1.33.

Adamis Pharmaceuticals (NASDAQ:ADMP) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Adamis Pharmaceuticals had a negative net margin of 205.32% and a negative return on equity of 86.04%. The company had revenue of $5.77 million during the quarter, compared to analyst estimates of $5.82 million. On average, research analysts expect that Adamis Pharmaceuticals Corp will post -0.46 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of ADMP. Wedbush Securities Inc. increased its holdings in Adamis Pharmaceuticals by 139.8% during the second quarter. Wedbush Securities Inc. now owns 44,600 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 26,000 shares during the last quarter. National Asset Management Inc. lifted its stake in Adamis Pharmaceuticals by 28.9% in the 1st quarter. National Asset Management Inc. now owns 29,920 shares of the specialty pharmaceutical company’s stock valued at $64,000 after purchasing an additional 6,710 shares during the last quarter. A.R.T. Advisors LLC lifted its stake in Adamis Pharmaceuticals by 143.8% in the 2nd quarter. A.R.T. Advisors LLC now owns 61,711 shares of the specialty pharmaceutical company’s stock valued at $80,000 after purchasing an additional 36,400 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Adamis Pharmaceuticals in the 2nd quarter valued at about $181,000. Finally, Leisure Capital Management grew its holdings in Adamis Pharmaceuticals by 4.5% during the first quarter. Leisure Capital Management now owns 115,724 shares of the specialty pharmaceutical company’s stock worth $244,000 after purchasing an additional 4,967 shares during the period. Hedge funds and other institutional investors own 12.11% of the company’s stock.

Adamis Pharmaceuticals Company Profile (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Recommended Story: Technical Analysis of Stocks, How Can It Help

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.